FDA's CGMP Paperwork Notice: What It Does and Doesn't Change
On February 24, 2026, the Food and Drug Administration published a Federal Register notice inviting public comment on an information-collection burden estimate tied to its existing current good manufacturing practice (CGMP) regulations for dietary supplements [SRC: FR-2026-03589]. For anyone tracking supplement regulation, the headline is easy to overstate. This is not a proposal to rewrite manufacturing rules, add new testing requirements, or change what companies must do on the production floor. It is a procedural step required by a decades-old paperwork law, and understanding that distinction matters for reading the notice correctly.
What a Paperwork Reduction Act notice actually is
The Paperwork Reduction Act of 1995 (PRA) requires federal agencies to periodically justify, in public, the burden they impose on regulated industries through recordkeeping, reporting, and disclosure requirements. Under the PRA, agencies must publish a notice in the Federal Register whenever they propose a new collection of information or seek to extend an existing one, and they must allow 60 days for public comment [SRC: FR-2026-03589]. The FDA's February 2026 notice is explicitly framed this way: it solicits comments on the information-collection provisions embedded in the agency's existing dietary supplement CGMP regulations [SRC: FR-2026-03589].
In practice, this means the notice is about counting and justifying hours and costs, not about changing obligations. The underlying CGMP rule, which governs manufacturing, packaging, labeling, and holding operations for dietary supplements, already requires manufacturers to keep certain records, such as batch production records, testing results, and complaint files. The PRA process asks a narrower question: how much time and cost does the government estimate this recordkeeping consumes, and is that estimate accurate. The notice is a mechanism for the agency to justify its estimate to the public and, ultimately, to the Office of Management and Budget (OMB), rather than an announcement of new substantive requirements.
Distinguishing this notice from a proposed rule
It is worth being precise about document types, because the regulatory process uses several categories that carry different weight. A "proposed rule" changes or creates binding legal obligations and typically goes through notice-and-comment rulemaking under the Administrative Procedure Act. A "final rule" is a rule that has completed that process and carries the force of law. A "notice," by contrast, can serve many purposes — announcing a meeting, a guidance document, an enforcement action, or, as here, a paperwork burden estimate — without altering what is legally required. The February 2026 document is explicitly identified as a notice, and its subject is a "proposed collection" of information for comment purposes under the PRA, not a proposed rule that would modify CGMP obligations [SRC: FR-2026-03589]. Nothing in the abstract describes new manufacturing standards, revised testing protocols, or altered labeling requirements. The action lives entirely within the administrative machinery that supports an existing rule, not within the rule itself.
What the notice covers, in agency terms
The notice's stated purpose is to solicit public comment on the information-collection provisions of FDA's dietary supplement CGMP regulations [SRC: FR-2026-03589]. In PRA notices of this kind, agencies typically walk through several elements: the specific regulatory sections that trigger a collection of information, an estimate of how many respondents (here, dietary supplement manufacturers, packagers, and holders) are affected, an estimate of the average number of hours each respondent spends annually on the relevant recordkeeping or reporting activity, and a total estimated burden across the industry. The published abstract for this notice does not itself enumerate those specific hour or respondent figures in the material available here, so this article does not assign numbers to them. What can be said with confidence, based on the notice's own framing, is that its function is to test and refresh FDA's estimate of the paperwork burden associated with the existing CGMP recordkeeping structure, not to expand that structure [SRC: FR-2026-03589].
This kind of notice also serves as a formal opportunity for stakeholders — manufacturers, trade associations, consultants, or members of the public — to weigh in on whether FDA's burden estimate is realistic. Comments might argue that the agency has undercounted the time required for batch documentation, or conversely, that certain recordkeeping tasks have become more automated and therefore less burdensome than FDA assumes. Either way, the substance of the underlying CGMP requirements is not up for debate in this particular proceeding; only the accounting of the burden is.
The follow-up notice: moving toward OMB review
A second, related notice published on June 18, 2026, shows the next procedural step. That notice announces that the proposed collection of information has been submitted to the Office of Management and Budget for review and clearance under the PRA [SRC: FR-2026-12238]. This is a standard progression: after the initial 60-day public comment period on a Federal Register notice concludes, the agency typically revises its burden estimate as needed and then submits the collection package to OMB, which conducts its own review, often with an additional, shorter comment window, before granting or denying approval. The existence of this June follow-up notice indicates that the underlying information collection is still active and moving through the standard federal clearance process — it has not been withdrawn, and it has not yet been finally approved by OMB as of the notice's publication [SRC: FR-2026-12238]. Neither notice states an outcome; both describe steps in an ongoing administrative sequence.
Why this distinction matters for reading regulatory news
Federal Register notices about information collection are published routinely, often on a rolling basis, for many FDA-regulated categories, from drug labeling to food facility registration to dietary supplement CGMP records. Because these notices use formal, sometimes dense regulatory language and because they invoke the same underlying rule that governs manufacturing practice, it is easy for secondary coverage to conflate "FDA published something about CGMP" with "FDA is changing CGMP requirements." The packet examined here illustrates why that conflation is a mistake. The February 2026 notice is explicit that it operates under the Paperwork Reduction Act and concerns an existing collection of information tied to current regulations [SRC: FR-2026-03589]. The June 2026 follow-up is explicit that it concerns submission of that same collection to OMB for administrative review and clearance [SRC: FR-2026-12238]. Neither document contains language proposing new testing methods, ingredient identity requirements, batch-record content, facility inspection standards, or labeling rules. Readers should not infer that either notice signals an imminent change to what supplement manufacturers must do to comply with CGMP.
What CGMP already requires, in general terms
To understand why these paperwork notices exist at all, it helps to recall, in general terms, what the underlying CGMP framework for dietary supplements already asks of manufacturers. The regulations govern how supplements are manufactured, packaged, labeled, and held, and they include requirements for quality control, personnel qualifications, equipment maintenance, and recordkeeping. Recordkeeping is where the PRA becomes relevant: any time a regulation requires a company to create, retain, or submit records for the government's potential review, that requirement counts as an "information collection" under the PRA, and the agency must periodically justify the associated burden. This structure explains why a company operating under CGMP would already be maintaining records well before either of these 2026 notices appeared, and why neither notice changes the content of what must be recorded. The notices are about the government's obligation to periodically re-justify its own estimate of how much time that existing recordkeeping consumes across the industry — an administrative housekeeping function required by a law aimed at limiting unnecessary federal paperwork burdens, not a signal about new compliance obligations.
What the evidence does not show
It is important to be explicit about the limits of what these two notices establish, because regulatory notices are easy to over-read. First, neither notice changes, proposes to change, or hints at changing the substantive CGMP manufacturing, testing, or labeling requirements for dietary supplements. Both documents concern the administrative process of estimating and clearing a paperwork burden under the PRA, not rulemaking on manufacturing practice [SRC: FR-2026-03589] [SRC: FR-2026-12238]. Second, a notice seeking comment is not evidence of an agency decision. The February 2026 notice explicitly frames itself as an opportunity for public comment, which means the burden estimate under discussion is provisional and subject to revision based on stakeholder input [SRC: FR-2026-03589]. Comments submitted in response do not bind FDA to any particular outcome. Third, submission to OMB, as described in the June 2026 notice, is not the same as OMB approval. The notice states that the collection has been submitted for review and clearance; it does not state that clearance has been granted [SRC: FR-2026-12238]. Readers should not treat this step as a completed regulatory action. Fourth, these documents say nothing about enforcement priorities, inspection frequency, or specific compliance findings at any individual company. They are generic to the regulated population of dietary supplement manufacturers as a class and do not reference any particular firm, product, or violation. Fifth, this packet does not include the specific numeric burden estimates (respondent counts, hours per response, or total annual burden) that would typically appear in the full text of such notices. Without those figures in the supplied material, this article does not speculate about whether the estimated burden is rising, falling, or unchanged from prior estimates. Finally, nothing here should be read as legal advice about what a given manufacturer must do to comply with CGMP. Companies subject to these regulations should consult the current regulatory text and, where appropriate, qualified regulatory counsel, rather than inferring compliance obligations from a paperwork-burden notice.
The broader pattern: administrative maintenance, not policy shift
Viewed together, the two 2026 notices describe a single information collection moving through a routine, recurring administrative cycle: initial Federal Register notice and comment period, followed by submission to OMB for review and clearance [SRC: FR-2026-03589] [SRC: FR-2026-12238]. This cycle recurs periodically for essentially every standing information collection maintained by a federal agency, as required by the PRA. It is a feature of ordinary regulatory maintenance, not a leading indicator of substantive policy change. For readers trying to track meaningful shifts in dietary supplement quality standards, the more consequential documents to watch are proposed or final rules that explicitly modify the CGMP regulatory text itself, agency guidance documents that reinterpret existing requirements, or enforcement actions that reveal how FDA is applying current rules in practice. A PRA notice about an existing collection's paperwork burden, by contrast, is best read as confirmation that the underlying framework remains in force and that the agency is fulfilling its statutory obligation to periodically account for the cost of compliance it imposes — nothing more.
Selected Sources
- FDA, Agency Information Collection Activities; Proposed Collection; Comment Request; CGMP for Dietary Supplements (Federal Register, Feb. 24, 2026) [SRC: FR-2026-03589]
- FDA, Agency Information Collection Activities; Submission for OMB Review; CGMP for Dietary Supplements (Federal Register, Jun. 18, 2026) [SRC: FR-2026-12238]
Editorial Note
This article is based solely on the two Federal Register notices supplied for this assignment. It describes the Paperwork Reduction Act process these notices document and does not draw on the full regulatory text of FDA's dietary supplement CGMP rule, prior years' burden estimates, or any public comments submitted in response. Readers seeking the current, complete CGMP requirements should consult the Code of Federal Regulations and official FDA guidance directly.
This article is for educational purposes only and has not been evaluated by the Food and Drug Administration. It is not intended to diagnose, treat, cure, or prevent any disease, and it does not provide legal or regulatory compliance advice.
